Compare abrdn Income Credit Strategies Fund (ACP) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Gilead Sciences, Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $637.39M), while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 258.9× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (18.31%). Which is the better fit depends on your goals.
| ACP | GILD | |
|---|---|---|
Market Cap | $637.39M | $164.99B |
Sector | Financials | Health |
52-Week High | $5.98 | $155.80 |
52-Week Low | $5.01 | $110.56 |
Dividend Yield | 18.31% | 2.47% |
Enterprise Value | — | $188.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.08, up 0.4% today, with a bearish technical signal from moving averages and a neutral stance from oscillators. The stock shows a low P/E of 7.7 and P/B of 0.9, indicating potential undervaluation, while net income margin remains high at 95.31%. Recent news highlights dividend declarations but also concerns over distribution sustainability from Seeking Alpha (2026-05-29).
The outlook is mixed: attractive valuation and dividends offer income appeal, but technical weakness and high distribution reliance pose risks. Investors should weigh the fund's high yield against credit spread tightness and leverage exposure noted in analyst reports.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
